Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Revenue projections:

Revenue projections for BIOCON
Revenue projections for BIOCON

Revenues for BIOCON are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 1.136000
forwardPE 28.003813
debtToEquity 66.259000
earningsGrowth 1.547000
revenueGrowth 0.128000
grossMargins 0.659440
operatingMargins 0.145320
trailingEps 8.460000
forwardEps 9.920000

The current ratio for BIOCON is 1.136, indicating that the company can service its short-term debt using available cash and assets. This suggests BIOCON has strong liquidity, with more than enough resources to meet its immediate financial commitments.
BIOCON's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
BIOCON's positive earnings and revenue growth point to business expansion on the horizon. The company is positioned for continued success, with increasing profits and revenue growth highlighting a strong path forward for future growth.
Biocon Limited's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that Biocon Limited is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.

Price projections:

Price projections for BIOCON
Price projections for BIOCON

BIOCON's stock price has consistently been near the lower edge of expected values, indicating potential struggles in meeting growth projections. This trend may reflect a cautious market sentiment toward the company.

Insider Transactions:

Insider Transactions for BIOCON
Insider Transactions for BIOCON


Recent trading of BIOCON stock saw 1 sales, with market price at 264.1499938964844 per share.No sell transactions occurred in the period under review.Investors are purchasing Biocon Limited more frequently than selling it near the current price levels, which might point to a bullish sentiment. This pattern could be interpreted as a favorable outlook for the stock's future.

Recommendation changes over time:

Recommendations trend for BIOCON
Recommendations trend for BIOCON


Analysts have shown a buy bias for BIOCON, marking it as a favorable investment option. This could inspire investors to see BIOCON as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.